Interacting Drugs |
Voriconazole vs Reverse Transcriptase Inhibitors (Non-Nucleoside) |
Security Level |
 |
Mechanism |
Reverse Transcriptase Inhibitors (Non-Nucleoside): May decrease the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). |
Management |
Efavirenz and voriconazole should not be coadministered at standard doses. Concurrent use is acceptable if voriconazole is dosed at 400 mg every 12 hours and efavirenz is dosed at 300 mg daily (adult doses) throughout the course of therapy. Exceptions: Delavirdine; Etravirine; Rilpivirine. |
Voriconazole vs Reverse Transcriptase Inhibitors (Non-Nucleoside)
Post Review about Voriconazole vs Reverse Transcriptase Inhibitors (Non-Nucleoside) Click here to cancel reply.
Other Interactions of Voriconazole
Other Interactions of Reverse Transcriptase Inhibitors (Non-Nucleoside)
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.